Contribution of Corticospinal and Reticulospinal Mechanisms to Neural Adaptations Induced by Muscle Strengthening of Healthy Adults (RenfoRS)
This controlled trial aims to investigate the neural adaptations induced by a 4-week resistance training program targeting the triceps surae muscles. Specifically, the study will examine the contribution of the corticospinal and reticulospinal pathways to the nervous adaptations associated with resistance training. It will give us more information about the nervous pathways mediating adaptations following this type of training. The main question it aims to answer is: What is the contribution of the cortico- and reticulospinal tracts to the nervous adaptations following a resistance training program?
Participants will take part to a resistance training program of the triceps surae for 4 weeks. They will undergo assessments of corticospinal and reticulospinal excitability before and after the training intervention to determine changes in neural pathways
The findings will improve our understanding of the neural mechanisms underlying strength gains following resistance training.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female participants aged 18 to 40 years
- Willing and able to provide written informed consent
- No regular participation (>1 session per week) in resistance training aimed at increasing maximal strength
- Affiliated with, or beneficiary of, a social security system
Exclusion Criteria:
- Personal or family history of epilepsy
- Conditions associated with a significantly reduced seizure threshold, including sleep deprivation, extreme fatigue, or jet lag
- Use of medications or substances known to lower the seizure threshold
- Use of medications that may influence neurophysiological measures (e.g., neuroleptics, anxiolytics, antidepressants, anticonvulsants)
- Presence of cardiac pacemakers or other implanted devices that may interfere with magnetic fields
- Presence of metallic implants (mechanical or electronic), including cochlear implants, cranial implants, cardiac or neural stimulators, drug infusion pumps, magnetic aneurysm clips, or cerebrospinal fluid shunts
- Presence of non-removable metallic objects
- Presence of intraocular or intracranial metallic foreign bodies
- Known hearing disorders (e.g., tinnitus)
- History of psychiatric or neurological disorders
- Presence of severe cardiac or respiratory disease
- History of severe traumatic brain injury with loss of consciousness
- History of brain lesions of vascular, tumoral, infectious, or metabolic origin (e.g., stroke)
- History or presence of bleeding disorders (e.g., venous or arterial thrombosis, thrombophlebitis)
- Individuals currently under an exclusion period from another research study
- Individuals listed under Articles L.1121-5 to L.1121-8 and L.1121-12 of the French Public Health Code, including:
- Pregnant, parturient, or breastfeeding women
- Women of childbearing potential not using effective contraception
- Individuals deprived of liberty by judicial or administrative decision
- Adults under legal protection (guardianship, curatorship, or legal safeguard) or unable to provide consent and not under such protection
- Minors
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Resistance training group
|
Participants will complete a 4-week resistance training program targeting the triceps sure muscles (3 sessions per week). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the change in maximum force achieved during a maximal voluntary contraction (MVC) of plantar flexion (the primary action of the triceps surae muscles).
Time Frame: At baseline (before the first exercise session) and immediately after completion of the exercise sessions
|
The maximum force, achieved during a maximal voluntary contraction (MVC), will be recorded using an isokinetic ergometer (Biodex Medical Systems Inc., Shirley, NY, USA). |
At baseline (before the first exercise session) and immediately after completion of the exercise sessions
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The changes in the amplitude of electrophysiological responses evoked by magnetic or electrical stimulation at different levels of the neuromuscular system (cortical, thoracic, peripheral nerve).
Time Frame: During intervention
|
Electrophysiological responses will be recorded using surface electromyography (sEMG), with electromyography electrodes (Contrôle Graphique Medical, Brie-Compte-Robert, France) placed on the muscle surface of the muscles under study. The following techniques will be used to elicit these responses, whether or not they are conditioned by auditory stimulation: intense auditory stimulation at 115 dB (SSI) coupled with a visual stimulus (i.e., the illumination of a red light-emitting diode, LED); non-intense auditory stimulation at 70 dB (SS) coupled with the illumination of a red LED; the illumination of the red LED without any sound stimulation (V). |
During intervention
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C25-84
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.